FINNENCE ▪ THE WIRE FILE
THE WIRE · № 73291
News■ Unclear/unknown
Commonwealth Care Alliance® Senior Care Options Plan Achieves 4.5 Star Quality Rating from the Centers for Medicare and Medicaid Services
KINDNews
DIRECTION■ Unclear/unknown
SOURCES1
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-09 16:00 UTC
LAST UPDATE2026-10-09 16:00 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
A Medicare plan star rating affects that plan's enrollment, not broad healthcare assets.
Private insurer quality rating, no ticker
CATALYST TO WATCH
Enrollment period results
MAIN RISK
Rating could change next cycle
FULL DISPATCH
CCA health plan ranks among top 16% of plans nationally in high‑quality, coordinated care BOSTON, Oct. 9, 2026 /PRNewswire/ -- Commonwealth Care Alliance (CCA), a mission-driven healthcare services organization offering innovative health plans and care delivery programs designed for...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
CONTEXTHealthcare
04 RECEIPTS
THE SOURCE RECORD.
1 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
New Mexico insurance officials approve nearly 20% average rate hike for small group plans2026-10-09 13:44 UTC
New Mexico insurance officials approve nearly 20% average rate hike for small group plans2026-10-09 13:44 UTC
→CORRELATIONshares Healthcare
Eli Lilly-Backed Biotech TRex Dips 3.6% After $116.7 Million IPO2026-10-09 16:03 UTC
Eli Lilly-Backed Biotech TRex Dips 3.6% After $116.7 Million IPO2026-10-09 16:03 UTC
→CORRELATIONshares Healthcare
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules2026-10-09 16:30 UTC
WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules2026-10-09 16:30 UTC
←CORRELATIONshares Healthcare
TRex rakes in $117M IPO, while Retension reveals $45M listing2026-10-09 08:29 UTC
TRex rakes in $117M IPO, while Retension reveals $45M listing2026-10-09 08:29 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Sanofi2026-10-09 12:00 UTC
Phase 3 results posted: Study to Assess the Efficacy, Safety, and Tolerability of SAR440340/REGN3500/Itepekimab in Chronic Obstructive Pulmonary Disease (COPD) — Sanofi2026-10-09 12:00 UTC
←CORRELATIONshares Healthcare
Phase 3 results posted: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer — Hoffmann-La Roche2026-10-09 12:00 UTC
Phase 3 results posted: A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer — Hoffmann-La Roche2026-10-09 12:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.